公开(公告)号：US20240294508A1

公开(公告)日：2024-09-05

申请号：US18561308

申请日：2022-05-16

申请人： SIRONAX LTD.

发明人： Zhaolan ZHANG ,  Zhiyuan ZHANG ,  Yaning SU ,  Yanping XU

IPC分类号： C07D403/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC分类号： C07D403/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： Provided herein are compounds of Formula Ia and Ib, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling

公开(公告)号：US20230416226A1

公开(公告)日：2023-12-28

申请号：US17998552

申请日：2021-05-20

申请人： SIRONAX LTD.

发明人： Zhaolan ZHANG ,  Zhiyuan ZHANG ,  Yaning SU ,  Yanping XU

IPC分类号： C07D401/14 ,  C07D403/14 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14

CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the persons health or condition.

公开(公告)号：US20230159492A1

公开(公告)日：2023-05-25

申请号：US17908583

申请日：2021-03-02

申请人： SIRONAX LTD.

发明人： Jianguang HAN ,  Zhiyuan ZHANG

IPC分类号： C07D401/12 ,  C07D211/34

CPC分类号： C07D401/12 ,  C07D211/34

摘要： Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

公开(公告)号：US20240360114A1

公开(公告)日：2024-10-31

申请号：US18293357

申请日：2022-08-09

申请人： SIRONAX LTD.

发明人： Jianguang HAN ,  Weijie HOU ,  Zhiyuan ZHANG ,  Yanping XU ,  Yimin JIANG ,  Xingyu XU

IPC分类号： C07D413/04 ,  A61K31/4427 ,  A61K31/47 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  C07C211/48 ,  C07D213/74 ,  C07D215/10 ,  C07D215/16 ,  C07D241/04 ,  C07D265/30 ,  C07D401/04 ,  C07D413/14 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC分类号： C07D413/04 ,  A61K31/4427 ,  A61K31/47 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  C07C211/48 ,  C07D213/74 ,  C07D215/10 ,  C07D215/16 ,  C07D241/04 ,  C07D265/30 ,  C07D401/04 ,  C07D413/14 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

摘要： This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

公开(公告)号：US20210292305A1

公开(公告)日：2021-09-23

申请号：US17325200

申请日：2021-05-19

申请人： SIRONAX LTD

发明人： Zhiyuan Zhang ,  Yaning Su ,  Jianguang Han ,  Hanying Ruan ,  Ying Li ,  Guozheng Wang ,  Wendong Liu ,  Chong Zhang ,  Leiming Liang

IPC分类号： C07D403/12 ,  C07D403/06 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D405/12 ,  C07D403/14 ,  C07D413/14 ,  C07D513/04 ,  C07D487/04 ,  C07D471/04 ,  C07D231/06 ,  C07D401/06 ,  C07D401/14 ,  C07D495/04

摘要： The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

公开(公告)号：US20240327393A1

公开(公告)日：2024-10-03

申请号：US18574309

申请日：2022-07-08

申请人： SIRONAX LTD.

发明人： Jianguang HAN ,  Zhiyuan ZHANG ,  Weijie HOU ,  Yimin JIANG ,  Yanping XU

IPC分类号： C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

CPC分类号： C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

摘要： Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

公开(公告)号：US20240217963A1

公开(公告)日：2024-07-04

申请号：US18549923

申请日：2022-03-17

申请人： SIRONAX LTD.

发明人： Yaning SU ,  Zhaolan ZHANG ,  Yanping XU ,  Zhiyuan ZHANG

IPC分类号： C07D417/14 ,  A61K31/4439 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

CPC分类号： C07D417/14 ,  A61K31/4439 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

摘要： It provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling.

公开(公告)号：US20230203019A1

公开(公告)日：2023-06-29

申请号：US17998546

申请日：2021-05-20

申请人： SIRONAX LTD.

发明人： Yaning SU ,  Zhaolan ZHANG ,  Zhiyuan ZHANG ,  Yanping XU

IPC分类号： C07D403/14 ,  C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D487/04

CPC分类号： C07D403/14 ,  C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D487/04

摘要： Provided are piperazine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), pharmaceutically acceptable salts, hydrates and stereoisomers thereof. Provided are also pharmaceutical compositions, methods of making, and methods of use which include treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

公开(公告)号：US12129221B2

公开(公告)日：2024-10-29

申请号：US17325193

申请日：2021-05-19

申请人： SIRONAX LTD

发明人： Zhiyuan Zhang ,  Yaning Su ,  Yi Yang ,  Guozheng Wang ,  Wendong Liu ,  Yongfen Ma ,  Yan Ren

IPC分类号： C07C233/13 ,  A61P25/28 ,  A61P31/12 ,  A61P35/00

CPC分类号： C07C233/13 ,  A61P25/28 ,  A61P31/12 ,  A61P35/00

摘要： The disclosed compounds inhibit cellular necrosis, and include corresponding sulfonamides, prodrugs and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

公开(公告)号：US20230192662A1

公开(公告)日：2023-06-22

申请号：US17998568

申请日：2021-05-20

申请人： SIRONAX LTD.

发明人： Yaning SU ,  Zhiyuan ZHANG ,  Zhaolan ZHANG ,  Yanping XU

IPC分类号： C07D403/12 ,  C07D403/14 ,  C07D491/107 ,  C07D401/14 ,  A61P39/00

CPC分类号： C07D403/12 ,  C07D403/14 ,  C07D491/107 ,  C07D401/14 ,  A61P39/00

摘要： The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.